A. Sinclair Dunlop - 01 Dec 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair A. Dunlop
Issuer symbol
APLS
Transactions as of
01 Dec 2023
Net transactions value
-$1,467,240
Form type
4
Filing time
05 Dec 2023, 16:21:24 UTC
Previous filing
21 Nov 2023
Next filing
15 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $1,467,240 -24,000 -11% $61.14 192,679 01 Dec 2023 Indirect Owner (Epidarex) F1, F2
holding APLS Common Stock 122,403 01 Dec 2023 Direct
holding APLS Common Stock 31,855 01 Dec 2023 Indirect Owner (Masa) F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $60.850 - $61.440. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The securities are held by Epidarex Capital I, LP ("Epidarex") and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F3 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.